Physician profile
Yasodha Natkunam
NPI 1033261151
$38,048.90
in general payments reported to CMS, 2019-2025
11 companies · $17K in 2025
The $17K reported for 2025 was more than what 97% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,083 · 2020: $3,013 · 2021: $2,978 · 2022: $5,000 · 2023: $1,844 · 2024: $6,713 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,503 · Travel and Lodging: $1,734 · Education: $850 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $229 · Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,500.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,503.46 |
| Travel and Lodging | $1,733.63 |
| Education | $850.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $228.66 |
| Food and Beverage | $159.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leica Microsystems INC. | $10,000.00 | 2022-2024 | Bond-Prime Automated Stainer, Bond-III Processing Module |
| Beckman Coulter, INC. | $10,000.00 | 2025 | |
| Ventana Medical Systems, INC. | $7,696.05 | 2021-2025 | |
| Roche Molecular Systems, INC. | $3,935.33 | 2024-2025 | |
| Genentech, INC. | $1,977.50 | 2021 | |
| F. Hoffmann-La Roche Ag | $1,977.50 | 2020 | |
| Stemline Therapeutics INC. | $1,050.00 | 2019 | |
| Chugai Pharmaceutical Co., Ltd. | $1,035.83 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $252.09 | 2023 | |
| Taiho Oncology, INC. | $91.46 | 2023 | |
| Seagen INC. | $33.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yasodha Natkunam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.